Hormone therapy of prostate cancer: Is there a role for antiandrogen monotherapy?

Francesco Boccardo

Research output: Contribution to journalArticlepeer-review


Androgen suppressive maneuvers still represent the gold standard for prostate cancer patients. However, they are associated with side effects (fatigue, sexual impotence, hot flushes, anemia, anxiety, depression and osteoporosis) all of which have a negative impact on quality of life. Nonsteroidal antiandrogens compete with dihydrotestosterone for the linkage of its own receptors. These compounds are commonly used in combination with suppressive maneuvers. However, there is a growing experience with them as monotherapy, based on the possibility to spare gonadal function and therefore prevent the effects related to its suppression. Many studies have demonstrated the feasibility and safety of this approach, which can represent a valuable alternative to suppressive maneuvers for patients wishing to retain sexual function, especially for those without distant metastases. Unfortunately, none of the comparative studies performed so far had the power to detect the equivalence between monotherapy and castration. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)121-132
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - Aug 2000


  • Antiandrogen monotherapy
  • Hormone therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Hormone therapy of prostate cancer: Is there a role for antiandrogen monotherapy?'. Together they form a unique fingerprint.

Cite this